{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:57:48Z","timestamp":1777910268428,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","content-domain":{"domain":["bprch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.beha.2013.10.007","type":"journal-article","created":{"date-parts":[[2013,10,16]],"date-time":"2013-10-16T00:24:02Z","timestamp":1381883042000},"page":"269-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["New agents: Great expectations not realized"],"prefix":"10.1016","volume":"26","author":[{"given":"Jeffrey E.","family":"Lancet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2013.10.007_bib1","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2012.42.2964","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia","volume":"30","author":"Burnett","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.007_bib2","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2013.10.007_bib3","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2010-05-285387","article-title":"Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm","volume":"116","author":"Walter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.007_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.beha.2013.10.007_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2009.24.2008","article-title":"Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia","volume":"28","author":"Schiller","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.007_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.2009.23.3130","article-title":"Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.007_bib7","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-01-198093","article-title":"A\u00a0randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.007_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3324\/haematol.2012.066613","article-title":"Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia","volume":"98","author":"Sekeres","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2013.10.007_bib9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2006-04-014357","article-title":"A\u00a0phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia","volume":"109","author":"Lancet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.007_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2013.10.007_bib11","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2007-09-112730","article-title":"A\u00a02-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia","volume":"111","author":"Raponi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.007_bib12","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.007_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/onc.2012.48","article-title":"Clonal evolution of acute leukemia genomes","volume":"32","author":"Jan","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.beha.2013.10.007_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In\u00a0vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2013.10.007_bib15","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1200\/JCO.2010.30.5961","article-title":"First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia","volume":"29","author":"Feldman","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2013.10.007_bib16","article-title":"Phase 2b randomized study of CPX-351 vs cytarabine (CYT)+daunorubicin (DNR) (7+3 regimen) in newly diagnosed AML patients aged 60-75","volume":"116","author":"Lancet","year":"2010","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2013.10.007_bib17","article-title":"Randomized phase 2 trial of timed-sequential therapy (TST) with flavopiridol (Alvocidib), Ara-C and mitoxantrone (FLAM) versus \u201c7+3\u201d for adults ages 70 years and under with newly diagnosed acute myeloid leukemia (AML)","volume":"120","author":"Zeidner","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2013.10.007_bib18","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2013.10.007_bib19","article-title":"Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients >60 years of age with FLT3 ITD positive or negative relapsed\/refractory acute myeloid leukemia","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.beha.2013.10.007_bib20","volume":"120","author":"Levis","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692613000650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:53:40Z","timestamp":1539305620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692613000650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1521692613000650"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2013.10.007","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New agents: Great expectations not realized","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2013.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}